Pharmaceutical manufacturer Eli Lilly has announced that it will seek approval from the Food and Drug Administration (FDA) to market the weight loss drug orforglipron. According to the New York Times, the GLP-1 drug is administered in a daily pill, unlike popular injectable GLP-1s like Ozempic and Wegovy. Participants in Lilly's clinical trials lost an average of 27.3 pounds each.
Related Posts
Florists’ secrets for keeping cut flowers fresh
Florists say cut flowers will use water faster and wilt faster if they are placed in bright sunlight or in drafty locations. The cooler they are kept, the…
Broken toes aren’t always a DIY fix
Many of us have experienced it at some point — stubbing a toe so hard that it swells and bruises, and wiggling it is too painful to attempt. It’s…
Exercise to store fat?
This may seem counter-intuitive. Researchers say the more you exercise, the better you store fat. But wait! Isn’t the whole point of exercise not to be…